Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

November 2022

Diadem Builds Out Executive Team As It Prepares for Commercialization of Its AlzoSure® Predict Prognostic Test for Alzheimer's Disease

Our Zoner Diadem, a company developing the first blood-based test for the early prediction of progression to Alzheimer's disease (AD), announced key additions to its senior management team. Sam Agus, MD, has been appointed Chief Medical Officer (CMO), James Clark, PhD, has been named Head, External Affairs and Collaborations, and Peter Bream is Diadem's new Chief Financial Officer (CFO). They join Simona Piccirella, PhD, Vice President of Operations and Development and Chief Executive Officer Paul Kinnon at Diadem.
Paul Kinnon
CEO at Diadem


We are pleased to welcome these highly experienced executives to Diadem as we prepare for the commercialization of our revolutionary AlzoSure® Predict blood test that can accurately identify whether or not an individual will progress to Alzheimer's as much as six years before symptoms of the disease are apparent. Sam, James and Peter are seasoned executives with decades of success in building and leading pharmaceutical, diagnostics and life science organizations. Simona has already played a major role in growing Diadem and developing the AlzoSure technology to this stage. Their contributions will be instrumental as we prepare for the commercialization of AlzoSure® Predict in the new year.